Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies
An erratum to this article was published (Pituitary, 21 May 2025 ↗)
Authors' conclusion
Patients with Cushing's disease and comorbid hypertension/diabetes receiving osilodrostat had rapid and sustained improvements in SBP/DBP and glycemic control, respectively.
Study context
- Population
- Patients with CD, with/without hypertension or DM at baseline
- Participants
- 210 patients
- Outcome
- Changes from baseline in SBP, DBP, FPG and HbA1c during osilodrostat treatment
Methodological detailsLINC 3 and LINC 4, 48-week core phase, optional open-label extension
- LINC 3 and LINC 4
- 48-week core phase
- Optional open-label extension
Pooled result
As reported in the abstract
BP and glycaemic control · W72
- Baseline hypertension
- 82.9%
- Baseline DM
- 40.0%
- Hypertension: reductions in mean SBP/DBP
- W12 to W72
- Hypertension with high SBP/DBP (>130/>90 mmHg) at baseline normotensive at W72
- 49.1%/58.5%
- DM: mean fasting plasma glucose (FPG) and HbA1c decreased
- W12 to W72
- DM with high FPG/HbA1c (≥100 mg/dL/≥6.5%) at baseline normal at W72
- 33.3%/61.5%
Further pooled results
Antihypertensive medication
- Dose reduced/stopped
- 26.8%
- Proportion taking: baseline vs W72
- 54.3% vs 47.3%
Antihyperglycaemic medication
- Dose reduced/stopped
- 35.7%
- Proportion taking: baseline vs W72
- 21.9% vs 17.1%
Correlates of improvement
- Improvements in SBP/DBP and FPG/HbA1c correlated with improvement in mean UFC but not weight change
Patients without hypertension/DM at baseline
- Blood pressure (BP)/glycaemic parameters generally remained normal
Original publication
Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies. Pituitary. Published 25 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →